eNSAID Technology

NOSH Platform and enhanced NSAIDs

NOSH Platform

The patented NOSH platform, developed in the laboratory of Dr Kashfi at the City University of New York (CUNY)  allows the rapid development of enhanced NSAIDs. These eNSAIDs are designed from existing NSAID scaffolds to release key signaling gases, nitric oxide and hydrogen sulfide on dosing. In addition to retaining the baseline activity of the parent NSAID, these eNSAIDs have been shown to possess:

  • Enhanced activity against cancer
  • Enhanced safety with the potential of long term dosing
  • Applicability to potential new indications
eNSAIDs are designed to release nitric oxide and hydrogen sulfide, which compensate for NSAID induced low prostaglandin levels, increasing mucosal blood flow and mucosal repair.  However,  eNSAIDs activity is greater than the sum of their constituent parts. Of the eNSAIDs tested, NBS-1120 has the most promising anti-tumor activity and is in active devlopment.

The NOSH technology platform is protected by multiple issued worldwide patents.  

Beyond Cancer

In addition to the treatment of cancer, eNSAIDs would be useful for indications where chronic dosing with NSAIDs is desirable, but currently not feasible such as in the treatment of  chronic inflammatory pain (RA, back pain, post-surgical applications), prevention of cancer in high risk populations and treatment and prevention of Alzheimer’s and Parkinson’s Diseases.

Importantly, the ability to administer anti-inflammatory drugs chronically at relatively high doses could enable their use as alternatives to opioids and help combat the opioid epidemic.

Finally, eNSAIDs have agrochemical applications where nitric oxide and hydrogen sulfide, both powerful plant signaling molecules, prime the organism against abiotic stress such as drought, salinity, and heat.